Immunomedics Develops Potential New Treatment Regimen for Non ... MarketWatch (press release) ... they are combined with chemotherapy, such as rituximab + CHOP (R-CHOP) for ... and rituximab + hyper-fractionated CVAD for mantle cell lymphoma (MCL). Immunomedics Reports Experience With Epratuzumab, Veltuzumab ... |
